Clinical Trial Update: A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Pumitamig to Pembrolizumab in previously untreated advanced non-small cell lung cancer with PD-L1 ≥ 50%; currently recruiting i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Pumitamig

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING